10X GENOMICS INC-CLASS A (TXG)

US88025U1097 - Common Stock

15.9  +0.26 (+1.66%)

Premarket: 15.91 +0.01 (+0.06%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

10X GENOMICS INC-CLASS A

NASDAQ:TXG (11/11/2024, 8:06:48 PM)

Premarket: 15.91 +0.01 (+0.06%)

15.9

+0.26 (+1.66%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-36.43%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.92B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TXG Daily chart

Company Profile

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,259 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Company Info

10X GENOMICS INC-CLASS A

6230 Stoneridge Mall Road

Pleasanton CALIFORNIA 94588

P: 19254017300

CEO: Serge Saxonov

Employees: 1259

Website: https://www.10xgenomics.com/

TXG News

News Image12 days ago - 10x Genomics, Inc.TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

/PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Cure51...

ChartMill News Image14 days ago - ChartmillThese stocks are moving in today's after hours session

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

News Image14 days ago - 10x Genomics, Inc.10x Genomics Reports Third Quarter 2024 Financial Results

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended...

News Imagea month ago - 10x Genomics, Inc.10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended...

News Imagea month ago - Investor's Business Daily10x Genomics Crashes After 'Disruptive' Reorg Upsets Third-Quarter Sales

The company is undergoing a reorganization that has proven more "disruptive" than previously expected.

News Imagea month ago - 10x Genomics, Inc.10x Genomics Announces Preliminary Select Third Quarter 2024 Results

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter...

TXG Twits

Here you can normally see the latest stock twits on TXG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example